1. Search Result
Search Result
Results for "

failure

" in MCE Product Catalog:

113

Inhibitors & Agonists

9

Screening Libraries

5

Peptides

1

Inhibitory Antibodies

16

Natural
Products

10

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas
  • HY-101729
    Anti-Heart Failure Agent 1

    Others Cardiovascular Disease
    Anti-Heart Failure Agent 1 an orally available compound suitable for the treatment of heart failure without inducing nausea, vomiting and restlessness.
  • HY-135363
    Valsartan Ethyl Ester

    Angiotensin Receptor Cardiovascular Disease
    Valsartan Ethyl Ester is an impurity of Valsartan. Valsartan is an angiotensin II receptor antagonist for the treatment of high blood pressure and heart failure.
  • HY-124899
    Hh-Ag1.5

    SAg1.5

    Hedgehog Metabolic Disease
    Hh-Ag1.5 (SAg1.5) is a potent Hedgehog (Hh) agonist with an EC50 of 1 nM. Hh-Ag1.5 mediated reprogramming breaks the quiescence of noninjured liver stem cells for rescuing liver failure.
  • HY-A0230A
    Spirapril hydrochloride

    SCH 33844 hydrochloride

    Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Spirapril (SCH 33844) hydrochloride is a potent angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Spirapril competitively binds to ACE and prevents the conversion of angiotensin I to angiotensin II. Spirapril is an orally active prodrug of Spiraprilat and can be used for the research of hypertension, congestive heart failure.
  • HY-139485
    BMS-986224

    HIV Cardiovascular Disease
    BMS-986224 is a potent, selective and orally bioavailable APJ receptor agonist (Kd = 0.3 nM). BMS-986224 exhibits similar receptor binding and signaling profile to (Pyr 1) apelin-13. BMS-986224 has the potential for the research of heart failure.
  • HY-103045
    CMPD101

    PKC ROCK Cardiovascular Disease
    CMPD101 is a potent, highly selective and membrane-permeable small-molecule inhibitor of GRK2/3 with IC50 of 18 nM and 5.4 nM, respectively. CMPD101 exhibits less selectively against GRK1, GRK5, ROCK-2 and PKCα with IC50s of 3.1 μM , 2.3 μM, 1.4 μM and 8.1 μM, respectively. CMPD101 can be used for the study of heart failure.
  • HY-131180
    BMS-986235

    LAR-1219

    Others Cardiovascular Disease
    BMS-986235 (LAR-1219) is a selective, orally active formyl peptide receptor 2 (FPR2) agonist, with EC50s of 0.41 nM and 3.4 nM for hFPR2 and mFPR2, respectively. BMS-986235 has potential for the prevention of heart failure.
  • HY-119850
    Aladorian

    ARM036

    Others Cardiovascular Disease
    Aladorian (ARM036) is a benzothiazepine derivative, with anti-arrhythmia effect. Aladorian is used for the research of heart failure and catecholaminergic polymorphic ventricular tachycardia.
  • HY-124873
    SERCA2a activator 1

    Calcium Channel Cardiovascular Disease
    SERCA2a activator 1 (Compound A) is a sarco/endoplasmic reticulum Ca 2+-dependent ATPase 2a (SERCA2a) activator. SERCA2a activator 1 attenuates phospholamban inhibition and enhances the systolic and diastolic functions of the heart. SERCA2a activator 1 can be used for heart failure.
  • HY-133036
    APJ receptor agonist 1

    Others Cardiovascular Disease
    APJ receptor agonist 1, a biphenyl acid derivative, is a potent APJ receptor (APJ-R) agonist (EC50s 0.093 and 0.12 nM for human and rat APJ-R, respectively). APJ receptor agonist 1 displays in vitro potency to apelin-13, the endogenous peptidic ligand for the APJ receptor. APJ receptor agonist 1 has the potential for the research of heart failure.
  • HY-B1477
    Clopamide

    Sodium Channel Metabolic Disease Cardiovascular Disease
    Clopamide is an orally active thiazide-like diuretic agent that inhibits the sodium-coupled chloride cotransporter SLC12A3. Clopamide has the potential for hypertension and cardiac failure research.
  • HY-18204
    Valsartan

    CGP 48933

    Angiotensin Receptor Cardiovascular Disease Endocrinology
    Valsartan (CGP 48933) is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research.
  • HY-B0592S
    Trandolapril D5

    RU44570 D5

    Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Trandolapril D5 (RU44570 D5) is a deuterium labeled Trandolapril (RU44570). Trandolapril is an orally active angiotensin converting enzyme (ACE) inhibitor for hypertension and congestive heart failure (CHF).
  • HY-19886
    F 16915

    Others Cardiovascular Disease
    F 16915, a Docosahexaenoic Acid (DHA, HY-B2167) derivative, is a potent pro-drug of DHA. F 16915 can prevent heart failure-induced atrial fibrillation.
  • HY-B0006A
    Carvedilol phosphate hemihydrate

    BM 14190 phosphate hemihydrate

    Adrenergic Receptor Autophagy Cancer Inflammation/Immunology Cardiovascular Disease
    Carvedilol phosphate hemihydrate (BM 14190 phosphate hemihydrate) is a non-selective β/α-1 blocker. Carvedilol phosphate hemihydrate inhibits lipid peroxidation with an IC50 of 5 μM. Carvedilol phosphate hemihydrate is a multiple action antihypertensive agent with potential use in angina and congestive heart failure. Carvedilol phosphate hemihydrate is an autophagy inducer that inhibits the NLRP3 inflammasome.
  • HY-14304A
    Zinterol hydrochloride

    MJ 9184 hydrochloride

    Adrenergic Receptor Cardiovascular Disease
    Zinterol hydrochloride (MJ 9184 hydrochloride) is a potent and selective β2-adrenoceptor agonist. Zinterol hydrochloride increases ICa in a concentration-dependent manner with an EC50 of 2.2 nM. Zinterol hydrochloride induces ventricular arrhythmias in conscious heart failure rabbits.
  • HY-B1469
    Isosorbide

    D-Isosorbide; Dianhydro-D-glucitol

    Others Metabolic Disease Cardiovascular Disease
    Isosorbide (D-Isosorbide), an orally active vasodilating agent that can be used for the research of heart failure and angina (chest pain). Isosorbide is also an oral hyperosmotic diuretic.
  • HY-B0006
    Carvedilol

    BM 14190

    Adrenergic Receptor Autophagy Cancer Inflammation/Immunology Cardiovascular Disease
    Carvedilol (BM 14190) is a non-selective β/α-1 blocker. Carvedilol inhibits lipid peroxidation in a dose-dependent manner with an IC50 of 5 μM. Carvedilol is a multiple action antihypertensive agent with potential use in angina and congestive heart failure. Carvedilol is an autophagy inducer that inhibits the NLRP3 inflammasome.
  • HY-107428
    PD-166793

    MMP Cardiovascular Disease
    PD-166793 is a potent, selective, orally active and wide‐broad spectrum inhibitor of MMP, exhibiting nanomolar potency against MMP-2, MMP-3 and MMP-13 (IC50=4, 7, and 8 nM, respectively) and micromolar potency vs MMP-1, -7 and -9 (IC50=6.0, 7.2, and 7.9 μM, respectively). PD-166793 can attenuate left ventricular remodeling and dysfunction in a rat model of progressive heart failure.
  • HY-B0247
    Torsemide

    Torasemide

    Others Metabolic Disease Cardiovascular Disease
    Torsemide (Torasemide) is an orally active loop diuretic. Torsemide has anti-aldosterone and vasodilatory effects. Torsemide also can be used for the research of heart failure, renal disease and hepatic cirrhosis.
  • HY-132613
    Lumasiran sodium

    Others Metabolic Disease
    Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) .
  • HY-113986
    (R)-Fadrozole

    (R)-CGS 16949A free base; FAD286

    Others Cardiovascular Disease
    (R)-Fadrozole ((R)-CGS 16949A; FAD286) is a potent nonsteroidal inhibitor. (R)-Fadrozole also inhibits human placental aromatase (pIC50 = 6.17) and aldosterone biosynthesis. (R)-Fadrozole reverses cardiac fibrosis in spontaneously hypertensive heart failure rats..
  • HY-109121
    Reldesemtiv

    CK-2127107

    Others Cardiovascular Disease
    Reldesemtiv (CK-2127107) is a selective, orally active and next-generation fast skeletal muscle troponin activator (FSTA). Reldesemtiv selectively activates fast skeletal myofibrils with an EC50 of 3.4 μM. Reldesemtiv increases exercise performance in a heart failure model.
  • HY-A0154
    Deslanoside

    Deacetyllanatoside C; Desacetyllanatoside C

    Na+/K+ ATPase Drug Metabolite Cardiovascular Disease
    Deslanoside (Desacetyllanatoside C) is a rapidly acting cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation. Deslanoside inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations .
  • HY-120274
    AZD9977

    Mineralocorticoid Receptor Metabolic Disease Cardiovascular Disease
    AZD9977 is a potent, selective, and orally active mineralocorticoid receptor (MR) modulator. AZD9977 is used for heart failure, and chronic kidney disease research.
  • HY-14254
    Olprinone Hydrochloride

    Loprinone Hydrochloride

    Phosphodiesterase (PDE) Cardiovascular Disease
    Olprinone (Loprinone) Hydrochloride is a potent phosphodiesterase (PDE) 3 inhibitor, with IC50s of 150, 100, 0.35 and 14 μM for PDE1, PDE2, PDE3 and PDE4, respectively. Olprinone Hydrochloride is used for the research of heart failure due to its positive inotropic and vasodilative effects. Anti-inflammatory activity.
  • HY-14254A
    Olprinone

    Loprinone

    Phosphodiesterase (PDE) Cardiovascular Disease
    Olprinone (Loprinone) is a potent phosphodiesterase (PDE) 3 inhibitor, with IC50s of 150, 100, 0.35 and 14 μM for PDE1, PDE2, PDE3 and PDE4, respectively. Olprinone is used for the research of heart failure due to its positive inotropic and vasodilative effects. Anti-inflammatory activity.
  • HY-B0368
    Captopril

    SQ 14225

    Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM.
  • HY-118643
    Cimlanod

    BMS-986231; CXL-1427

    Others Cardiovascular Disease
    Cimlanod (BMS-986231) is a second-generation Nitroxyl (HNO) donor for heart failure. Cimlanod (BMS-986231) delivers HNO via pH-dependent chemical breakdown when exposed to the neutral pH environment of the bloodstream. Cimlanod (BMS-986231) possesses positive lusitropic and inotropic as well as vasodilatory effects.
  • HY-A0119
    Nitroprusside disodium dihydrate

    Sodium nitroprusside dihydrate; Sodium Nitroferricyanide(III) Dihydrate

    Autophagy Cardiovascular Disease Cancer
    Nitroprusside disodium dehydrate (Sodium nitroprusside dihydrate) is a vasodilator that available for the research of acute hypertension, heart failure. Nitroprusside disodium dehydrate induces autophagy in glutathione-depleted osteoblasts. Nitroprusside disodium dehydrate acts as a nitric oxide (NO) donor in a rat intestinal ischemia reperfusion model.
  • HY-B0135A
    Furosemide sodium

    NKCC GABA Receptor Cancer Metabolic Disease
    Furosemide sodium is a potent and orally active inhibitor of Na +/K +/2Cl - (NKCC) cotransporter, NKCC1 and NKCC2. Furosemide sodium is also a GABAA receptors antagonist and displays 100-fold selectivity for α6-containing receptors than α1-containing receptors. Furosemide sodium acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema.
  • HY-B0135
    Furosemide

    NKCC GABA Receptor Metabolic Disease Cancer
    Furosemide is a potent and orally active inhibitor of Na +/K +/2Cl - (NKCC) cotransporter, NKCC1 and NKCC2. Furosemide is also a GABAA receptors antagonist and displays 100-fold selectivity for α6-containing receptors than α1-containing receptors. Furosemide acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema.
  • HY-131948
    3-Chlorodiphenylamine

    Potassium Channel Cardiovascular Disease
    3-Chlorodiphenylamine is a high affinity Ca 2+ sensitizer of cardiac muscle. 3-Chlorodiphenylamine is based on diphenylamine and binds to the isolated N-domain of cardiac troponin C (cTnC) (Kd=6 µM). 3-Chlorodiphenylamine is an excellent starting scaffold for the development of more potent Ca 2+-sensitizing compounds due to its small size, and can be used for systolic heart failure research.
  • HY-B0362A
    Phentolamine mesylate

    Phentolamine methanesulfonate

    Adrenergic Receptor Cardiovascular Disease Endocrinology
    Phentolamine mesylate (Phentolamine methanesulfonate) is a reversible, non-selective, and orally active blocker of α1 and α2 adrenergic receptor that expands blood vessels to reduce peripheral vascular resistance. Phentolamine mesylate can be used for the research of pheochromocytoma-related hypertension, heart failure and erectile dysfunction.
  • HY-103214
    Bucindolol

    Adrenergic Receptor Cardiovascular Disease Endocrinology
    Bucindolol is a β1-adrenergic receptor blocker, with intrinsic sympathomimetic activity, used in the research of heart failure.
  • HY-P2141A
    TRV-120027 TFA

    Angiotensin Receptor Cardiovascular Disease
    TRV120027 TFA, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages ß-arrestins while blocking G-protein signaling. TRV120027 TFA induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 TFA inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 TFA has the potential for the acute decompensated heart failure (ADHF) treatment.
  • HY-14286S
    Levosimendan D3

    Simsndan D3; OR-1259 D3

    Potassium Channel Phosphodiesterase (PDE) Autophagy Cardiovascular Disease
    Levosimendan D3 (Simsndan D3) is a deuterium labeled Levosimendan. Levosimendan is a calcium sensitiser used in the management of acutely decompensated congestive heart failure.
  • HY-78841
    (2S,4S)-Sacubitril

    Others Cardiovascular Disease
    (2S,4S)-Sacubitril is the impurity of Sacubitril. Sacubitril is a potent NEP inhibitor that can be used for the research of heart failure.
  • HY-P2141
    TRV-120027

    Angiotensin Receptor Cardiovascular Disease
    TRV120027, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages ß-arrestins while blocking G-protein signaling. TRV120027 induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 has the potential for the acute decompensated heart failure (ADHF) treatment.
  • HY-123348
    Sampatrilat

    UK-81252

    Angiotensin-converting Enzyme (ACE) Neprilysin Inflammation/Immunology Cardiovascular Disease
    Sampatrilat (UK-81252) is a potent and orally active vasopeptidase inhibitor of ACE and neutral endopeptidase (NEP). Sampatrilat inhibits C-domain ACE (Ki=13.8 nM) 12.4-fold more potent than that for the N-domain (Ki=171.9 nM). Sampatrilat (UK-81252) can be used for the study of chronic heart failure and blood pressure regulation.
  • HY-W050000
    OR-1855

    Potassium Channel Phosphodiesterase (PDE) Autophagy Cardiovascular Disease
    OR-1855, an active metabolite of Levosimendan, has effect on human myometrial contractility. Levosimendan is a calcium sensitiser used in the management of acutely decompensated congestive heart failure.
  • HY-U00025
    FR 58664

    Others Cardiovascular Disease
    FR 58664 is a drug to treat heart failure disease.
  • HY-P0012
    Aviptadil

    Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine)

    SARS-CoV Infection Inflammation/Immunology
    Aviptadil is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al.
  • HY-P0012A
    Aviptadil acetate

    Vasoactive Intestinal Peptide acetate salt (human, rat, mouse, rabbit, canine, porcine)

    SARS-CoV Infection Inflammation/Immunology
    Aviptadil acetate is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil acetate induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil acetate can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al.
  • HY-117281S
    Moexipril-d5

    Angiotensin-converting Enzyme (ACE) Apoptosis Cardiovascular Disease
    Moexipril-d5 is the deuterium labeled Moexipril. Moexipril hydrochloride is a potent orally active non-sulfhydryl angiotensin converting enzyme(ACE) inhibitor, which is used for the treatment of hypertension and congestive heart failure.
  • HY-U00209
    Benzofurodil

    Benfurodil; CB4091; Eudilat

    Others Cardiovascular Disease
    Benzofurodil is a cardiotonic, which is used for the chronic treatment of congestive heart failure.
  • HY-B0382S
    Fosinopril-d5 sodium

    Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Fosinopril-d5 sodium (SQ28555-d5 sodium) is the deuterium labeled Fosinopril sodium. Fosinopril Sodium is the ester prodrug of an angiotensin-converting enzyme (ACE) inhibitor, used for the treatment of hypertension and some types of chronic heart failure.
  • HY-14181
    Cinaciguat

    BAY 58-2667

    Guanylate Cyclase Cardiovascular Disease
    Cinaciguat is an activator of guanylate cyclase (sGC), and used for acute decompensated heart failure.
  • HY-B0542
    Ouabain Octahydrate

    Acocantherine; G-Strophanthin

    Na+/K+ ATPase Autophagy Cardiovascular Disease Cancer
    Ouabain Octahydrate is an inhibitor of Na +/K +-ATPase, used for the treatment of congestive heart failure.
  • HY-B1280
    Nikethamide

    N,N-Diethylnicotinamide

    Others Others
    Nikethamide, one of the respiratory central stimulants, has the potential for respiratory failure research.
  • HY-A0043A
    Cilazapril monohydrate

    Ro 31-2848 monohydrate

    Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Cilazapril Monohydrate is a angiotensin-converting enzyme (ACE) inhibitor used for the treatment of hypertension and congestive heart failure.
  • HY-A0043
    Cilazapril

    Ro 31-2848

    Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Cilazapril is a angiotensin-converting enzyme (ACE) inhibitor used for the treatment of hypertension and congestive heart failure.
  • HY-B0209
    Metolazone

    SR-720-22

    Thrombin Cardiovascular Disease
    Metolazone (SR-720-22) is primarily used to treat congestive heart failure and high blood pressure.
  • HY-14286
    Levosimendan

    Simsndan; OR-1259

    Potassium Channel Phosphodiesterase (PDE) Autophagy Cardiovascular Disease
    Levosimendan (Simsndan; OR-1259) is a calcium sensitiser used in the management of acutely decompensated congestive heart failure.
  • HY-18204A
    Sacubitril/Valsartan

    LCZ696

    Angiotensin Receptor Neprilysin Apoptosis Cardiovascular Disease Endocrinology
    Sacubitril/Valsartan (LCZ696), comprised Valsartan and Sacubitril (AHU377) in 1:1 molar ratio, is a first-in-class, orally bioavailable, and dual-acting angiotensin receptor-neprilysin (ARN) inhibitor for hypertension and heart failure. Sacubitril/Valsartan ameliorates diabetic cardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis.
  • HY-B0382
    Fosinopril sodium

    SQ28555

    Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Fosinopril Sodium is the ester prodrug of an angiotensin-converting enzyme (ACE) inhibitor, used for the treatment of hypertension and some types of chronic heart failure.
  • HY-113168
    Butyrylcarnitine

    Endogenous Metabolite Others
    Butyrylcarnitine is a metabolite in plasma, acts as a biomarker to improve the diagnosis and prognosis of heart failure, and is indicative of anomalous lipid and energy metabolism.
  • HY-B0780
    Fimasartan

    BR-A-657

    Angiotensin Receptor Apoptosis Cardiovascular Disease Endocrinology
    Fimasartan(BR-A-657) is a non-peptide angiotensin II receptor antagonist used for the treatment of hypertension and heart failure.
  • HY-N2356
    Apiosylskimmin

    Adicardin

    Others Metabolic Disease
    Apiosylskimmin (Adicardin), a coumarin isolated from Hydrangea macrophylla, has anti-chronic renal failure activity .
  • HY-19765
    GSK2798745

    TRP Channel Cardiovascular Disease
    GSK2798745 is a first-in-class, highly potent, selective, orally active transient receptor potential vanilloid 4 (TRPV4) ion channel blocker with IC50s of 1.8 and 1.6 nM for hTRPV4 and rTRPV4, respectively. GSK2798745 is used in research for the treatment of pulmonary edema associated with congestive heart failure.
  • HY-18206
    Lisinopril

    MK-521

    Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Lisinopril (MK-521) is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks.
  • HY-100239
    ICI 153110

    Phosphodiesterase (PDE) Cardiovascular Disease
    ICI 153110 is an orally active phosphodiesterase inhibitor with both vasodilating and inotropic properties which is designed for the treatment of congestive cardiac failure.
  • HY-B0378A
    Moexipril hydrochloride

    RS-10085

    Angiotensin-converting Enzyme (ACE) Apoptosis Cardiovascular Disease
    Moexipril hydrochloride is a potent orally active non-sulfhydryl angiotensin converting enzyme(ACE) inhibitor, which is used for the treatment of hypertension and congestive heart failure.
  • HY-18206A
    Lisinopril dihydrate

    MK-521 dihydrate

    Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Lisinopri dihydrate (MK-521 dihydrate) is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks.
  • HY-14873
    Tonapofylline

    BG 9928

    Adenosine Receptor Metabolic Disease Cardiovascular Disease
    Tonapofylline (BG 9928) is an orally active and selective adenosine A1 receptor antagonist with a Ki of 7.4 nM for human adenosine A1 receptor (hA1), which displays 915-fold selectivity versus human adenosine A2A receptor and 12-fold selectivity versus human adenosine A2B receptor and is used in development for the treatment of heart failure.
  • HY-15407
    Sacubitril

    AHU-377

    Neprilysin Cardiovascular Disease
    Sacubitril (AHU-377) is a potent NEP inhibitor with an IC50 of 5 nM. Sacubitril (AHU-377) is a component of the heart failure medicine LCZ696.
  • HY-15407A
    Sacubitril hemicalcium salt

    AHU-377 hemicalcium salt

    Neprilysin Cardiovascular Disease
    Sacubitril hemicalcium salt (AHU-377 hemicalcium salt) is a potent NEP inhibitor with an IC50 of 5 nM. Sacubitril hemicalcium salt is a component of the heart failure medicine LCZ696.
  • HY-B0932
    Levocarnitine propionate hydrochloride

    L-Propionylcarnitine chloride; ST-261

    Others Others
    Levocarnitine propionate hydrochloride (L-Propionylcarnitine chloride; ST-261) is used to treat the deterioration of renal function, congestive heart failure, intermittent claudication, and other diseases.
  • HY-122920
    Soyasaponin II

    HSV CMV Influenza Virus HIV NOD-like Receptor (NLR) Infection Inflammation/Immunology
    Soyasaponin II is a saponin with antiviral activity. Soyasaponin II inhibits the replication of HSV-1, HCMV, influenza virus, and HIV-1. Soyasaponin II shows potent inhibition on HSV-1 replication. Soyasaponin II serves as a inhibitor for YB-1 phosphorylation and NLRP3 inflammasome priming and could protect mice against LPS/GalN induced acute liver failure.
  • HY-B0130A
    Perindopril erbumine

    Perindopril tert-butylamine salt; S-9490 erbumine

    Angiotensin-converting Enzyme (ACE) Apoptosis Cardiovascular Disease Cancer
    Perindopril erbumine (Perindopril tert-butylamine salt) is a potent ACE inhibitor of which is used to treat high blood pressure, heart failure or stable coronary artery disease.
  • HY-B0130
    Perindopril

    S-9490

    Angiotensin-converting Enzyme (ACE) Cancer Cardiovascular Disease
    Perindopril (S-9490) is a long-acting ACE inhibitor of which is used to treat high blood pressure, heart failure or stable coronary artery disease.
  • HY-50919
    Paricalcitol

    VD/VDR Metabolic Disease
    Paricalcitol, a vitamin D analogue, is a vitamin D receptor agonist, used for the prevention and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic renal failure.
  • HY-Z0081
    2S,4R-Sacubitril

    Others Cardiovascular Disease
    2S,4R-Sacubitril is the impurity of Sacubitril. Sacubitril is approved by the Food and Drug Administration for use in combination with valsartan for the treatment of patients with heart failure.
  • HY-78847
    2R,4S-Sacubitril

    Others Cardiovascular Disease
    2R,4S-Sacubitril is the impurity of Sacubitril. Sacubitril is approved by the Food and Drug Administration for use in combination with valsartan for the treatment of patients with heart failure.
  • HY-78846
    2R,4R-Sacubitril

    Others Cardiovascular Disease
    2R,4R-Sacubitril is the impurity of Sacubitril. Sacubitril is approved by the Food and Drug Administration for use in combination with valsartan for the treatment of patients with heart failure.
  • HY-A0282
    L-Ornithine L-aspartate

    Others Metabolic Disease
    L-Ornithine L-aspartate is a stable salt of two natural nonessential L-amino acids: ornithine and aspartic acid. L-Ornithine L-aspartate lowers blood ammonia concentration and to eliminate symptoms of hepatic encephalopathy associated with liver cirrhosis.
  • HY-76585
    Paricalcitol-D6

    VD/VDR Metabolic Disease
    Paricalcitol-D6 is the deuterated form of Paricalcitol(Zemplar), which is a drug used for the prevention and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic renal failure.
  • HY-B0384
    Temocapril hydrochloride

    Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Temocapril hydrochloride is an angiotensin-converting enzyme (ACE) inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases.
  • HY-Z0075
    (Z)2S,4R-Sacubitril

    Others Cardiovascular Disease
    (Z)2S,4R-Sacubitril is the impurity of Sacubitril. Sacubitril is approved by the Food and Drug Administration for use in combination with valsartan for the treatment of patients with heart failure.
  • HY-18204S
    Valsartan D9

    CGP 48933 D9

    Angiotensin Receptor Cardiovascular Disease Endocrinology
    Valsartan D9 (CGP-48933 D9) is deuterium labeled valsartan. Valsartan is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research.
  • HY-B0235
    Trichlormethiazide

    Others Metabolic Disease
    Trichlormethiazide is an orally active thiazide diuretic, with antihypertensive effect. Trichlormethiazide increases urine volume (UV), Na and K excretion and tends to improve the depressed creatinine clearance (CCRE) in acute renal failure rats model.
  • HY-15450A
    INCB 3284

    CCR Endocrinology
    INCB 3284 is a potent, selective and orally bioavailable human CCR2 antagonist, inhibiting monocyte chemoattractant protein-1 binding to hCCR2, with an IC50 of 3.7 nM. INCB 3284 can be used in the research of acute liver failure.
  • HY-100713S
    Temocapril-d5

    Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Temocapril-d5 is the deuterium labeled Temocapril. Temocapril is an angiotensin-converting enzyme (ACE) inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases.
  • HY-N2037
    Higenamine

    Norcoclaurine

    Adrenergic Receptor Cardiovascular Disease Endocrinology
    Higenamine (Norcoclaurine), a β2-AR agonist, is a key component of the Chinese herb aconite root that prescribes for treating symptoms of heart failure in the oriental Asian countries. Higenamine (Norcoclaurine) has anti-apoptotic effects.
  • HY-B0592
    Trandolapril

    RU44570

    Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Trandolapril (RU44570) is a nonsulfhydryl prodrug that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI).
  • HY-B0251
    Eplerenone

    Epoxymexrenone

    Mineralocorticoid Receptor Cardiovascular Disease
    Eplerenone (Epoxymexrenone) is a selective, competitive and oreally active aldosterone antagonist with an IC50 of 138 nM. Eplerenone has low affinity for progesterone, androgen, estrogen and glucocorticoid receptors. Eplerenone can be used for hypertension and heart failure after myocardial infarction reserch.
  • HY-15450
    INCB 3284 dimesylate

    CCR Endocrinology
    INCB 3284 dimesylate is a potent, selective and orally bioavailable human CCR2 antagonist, inhibiting monocyte chemoattractant protein-1 binding to hCCR2, with an IC50 of 3.7 nM. INCB 3284 dimesylate can be used in the research of acute liver failure.
  • HY-N2037A
    Higenamine hydrochloride

    Norcoclaurine hydrochloride

    Adrenergic Receptor Cardiovascular Disease Endocrinology Cancer
    Higenamine hydrochloride (Norcoclaurine hydrochloride), a β2-AR agonist, is a key component of the Chinese herb aconite root that prescribes for treating symptoms of heart failure in the oriental Asian countries. Higenamine hydrochloride (Norcoclaurine hydrochloride) has anti-apoptotic effects.
  • HY-15407S
    Sacubitril-d4

    Neprilysin Cardiovascular Disease
    Sacubitril-d4 (AHU-377-d4) is the deuterium labeled Sacubitril. Sacubitril (AHU-377) is a potent NEP inhibitor with an IC50 of 5 nM. Sacubitril (AHU-377) is a component of the heart failure medicine LCZ696.
  • HY-B0130S
    Perindopril-d4 erbumine

    Angiotensin-converting Enzyme (ACE) Cancer Cardiovascular Disease
    Perindopril-d4 t-butylamine salt is the deuterium labeled Perindopril t-butylamine salt. Perindopril t-butylamine salt is a long-acting ACE inhibitor of which is used to treat high blood pressure, heart failure or stable coronary artery disease.
  • HY-14304
    Zinterol

    MJ 9184

    Adrenergic Receptor Cardiovascular Disease
    Zinterol (MJ 9184) is a potent and selective β2-adrenoceptor agonist. Zinterol increases ICa in a concentration-dependent manner with an EC50 of 2.2 nM.
  • HY-15746
    Dobutamine hydrochloride

    Adrenergic Receptor Cardiovascular Disease Endocrinology
    Dobutamine hydrochloride is a synthetic catecholamine that acts on α1-AR, β1-AR, β2-AR (α-1, β-1 andβ-2 adrenoceptors). Dobutamine hydrochloride is a selective β1-AR agonist, relatively weak activity at α1-AR and β2-AR. Dobutamine hydrochloride can increase cardiac output and correct hypoperfusion.
  • HY-129029
    Bisoprolol

    Adrenergic Receptor Cardiovascular Disease
    Bisoprolol is a potent, selective and orally active β1-adrenergic receptor blocker. Bisoprolol has little activity on β2-receptor and has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research.
  • HY-P2281
    Atrial natriuretic factor (1-28) (human, porcine)

    Atrial natriuretic peptide (1-28)

    Endogenous Metabolite Metabolic Disease Cardiovascular Disease
    Atrial natriuretic factor (1-28) (human, porcine) is a potent suppressor of pro-opiomelanocortin (POMC) mRNA but a weak inhibitor of βEP-LI release.
  • HY-N2333
    Resiniferatoxin

    (+)-Resiniferatoxin

    TRP Channel Cardiovascular Disease
    Resiniferatoxin ((+)-Resiniferatoxin), derived from the Euphorbia resinifera plant, is a selective transient receptor potential vanilloid 1 (TRPV1) receptor agonist. Resiniferatoxin eliminates TRPV1+ primary sensory afferents and blunt cardiac sympathetic afferent reflex for a relatively long period.
  • HY-B1294
    Amrinone

    Inamrinone

    Phosphodiesterase (PDE) Cardiovascular Disease
    Amrinone (Inamrinone) is a positive inotropic-vasodilator agent. Amrinone is a selective phosphodiesterase III inhibitor that increases cyclic adenosine monophosphate by preventing its breakdown. Amrinone is also an orally active, non-glycosidic and non-catecholamine cardiotonic agent.
  • HY-103193
    NKH477

    Colforsin dapropate hydrochloride

    Adenylate Cyclase Cardiovascular Disease
    NKH477 (Colforsin dapropate hydrochloride) directly activates the catalytic unit of adenylate cyclase and increases intracellular cAMP. NKH477 is a forskolin derivative that improves cardiac failure mainly through its beneficial effects on diastolic cardiac function. NKH477 exerts an antiproliferative effect in vivo with an altered cytokine profile to inhibit the acute rejection of rat orthotopic lung allografts.
  • HY-B1030
    Lanatoside C

    Autophagy Enterovirus Cardiovascular Disease Cancer
    Lanatoside C is a cardiac glycoside, can be used in the treatment of congestive heart failure and cardiac arrhythmia.Lanatoside C has an IC50 of 0.19 μM for dengue virus infection in HuH-7 cells. Lanatoside C can effectively inhibit all four serotypes of dengue virus, flavivirus Kunjin, alphavirus Chikungunya, Sindbis virus and the human enterovirus 71.
  • HY-12717AS
    Phentolamine-d4 hydrochloride

    Adrenergic Receptor Cardiovascular Disease Endocrinology
    Phentolamine-d4 (Phentolamine-d4) hydrochloride is the deuterium labeled Phentolamine hydrochloride. Phentolamine hydrochloride is a reversible, non-selective, and orally active blocker of α1 and α2 adrenergic receptor that expands blood vessels to reduce peripheral vascular resistance. Phentolamine hydrochloride can be used for the research of pheochromocytoma-related hypertension, heart failure and erectile dysfunction.
  • HY-N0107
    Cyclovirobuxine D

    Apoptosis Autophagy mTOR Akt Cardiovascular Disease
    Cyclovirobuxine D (CVB-D) is the main active component of the traditional Chinese medicine Buxus microphylla. Cyclovirobuxine D induces autophagy and attenuates the phosphorylation of Akt and mTOR. Cyclovirobuxine D inhibits cell proliferation of gastric cancer cells through suppression of cell cycle progression and inducement of mitochondria-mediated apoptosis. Cyclovirobuxine D is beneficial for heart failure induced by myocardial infarction.
  • HY-124687
    ROMK-IN-32

    Potassium Channel Cardiovascular Disease
    ROMK-IN-32 is a renal outer medullary potassium channel (ROMK) inhibitor with an IC50 of 35 nM. ROMK-IN-32 also inhibits hERG with an IC50 of 22 μM.
  • HY-125976
    ML233

    Others Cardiovascular Disease
    ML233 is a non-peptide based potent apelin receptor (APJ) agonist (EC50=3.7 μM). ML233 displays >21-fold selective over the closely related angiotensin 1 (AT1) receptor (>79 μM).
  • HY-122537A
    Arotinolol

    Adrenergic Receptor 5-HT Receptor Cardiovascular Disease
    Arotinolol is a nonselective α/β-adrenergic receptor blocker and a vasodilating β-blocker. Arotinolol also shows potency for inhibiting the binding of the radioligand 125I-ICYP to 5HT1B-serotonergic receptor sites. Arotinolol is an antihypertensive agent for the treatment of a variety of cardiovascular pathologies as well as non-cardiovascular diseases.
  • HY-B1639
    Enoximone

    Phosphodiesterase (PDE) Inflammation/Immunology Cardiovascular Disease
    Enoximone is an inotropic vasodilating agent and a selective and orally active phosphodiesterase III (PDE3) inhibitor with an IC50 of 5.9 μM. Enoximone induces vasodilatation and increases intracellular levels of cAMP by inhibiting cGMP-inhibited PDE. Enoximone also exhibits PDE4 inhibitory effect with an IC50 of 21.1 μM for myocardial PDE4A. Enoximone has the potential for congestive heart failure research and has bronchodilatory, antiasthma and anti-inflammatory effects.
  • HY-18346
    Mozavaptan

    OPC-31260

    Vasopressin Receptor Cancer Endocrinology Metabolic Disease
    Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment.
  • HY-123593
    Mozavaptan hydrochloride

    OPC-31260 hydrochloride

    Vasopressin Receptor Cancer Endocrinology Metabolic Disease
    Mozavaptan hydrochloride (OPC-31260 hydrochloride) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan hydrochloride shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan hydrochloride has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment.
  • HY-113618A
    RO2959 hydrochloride

    CRAC Channel Interleukin Related Cardiovascular Disease
    RO2959 hydrochloride is a potent and selective CRAC channel inhibitor with an IC50 of 402 nM. RO2959 hydrochloride is a potent blocker of store operated calcium entry (SOCE) mediated by Orai1/Stim1 channels with an IC50 of 25 nM. RO2959 hydrochloride is also a potent inhibitor of human IL-2 production, and potently blocks T cell receptor triggered gene expression and T cell functional pathways.
  • HY-113618B
    RO2959 monohydrochloride

    CRAC Channel Interleukin Related Cardiovascular Disease
    RO2959 monohydrochloride is a potent and selective CRAC channel inhibitor with an IC50 of 402 nM. RO2959 monohydrochloride is a potent blocker of store operated calcium entry (SOCE) mediated by Orai1/Stim1 channels with an IC50 of 25 nM. RO2959 monohydrochloride is also a potent inhibitor of human IL-2 production, and potently blocks T cell receptor triggered gene expression and T cell functional pathways.
  • HY-10965
    Rolofylline

    KW-3902

    Adenosine Receptor Neurological Disease
    Rolofylline (KW-3902) is a potent, selective adenosine A1 receptor antagonist that is under development for the treatment of patients with acute congestive heart failure and renal impairment. Rolofylline is metabolized primarily to the pharmacologically active M1-trans and M1-cis metabolites by cytochrome P450 (CYP450). Rolofylline is alleviating the presynaptic dysfunction and restores neuronal activity as well as dendritic spine levels in vitro, is an interesting candidate to combat the hypometabolism and neuronal dysfunction associated with Tau-induced neurodegenerative diseases.
  • HY-113432
    Nudifloramide

    2PY

    Endogenous Metabolite PARP Metabolic Disease
    Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro.
  • HY-P9917
    Tocilizumab

    Anti-Human IL6R, Humanized Antibody

    Interleukin Related Cancer Inflammation/Immunology
    Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease).
  • HY-106994
    Nebentan

    YM598 free base

    Endothelin Receptor Inflammation/Immunology Cardiovascular Disease
    Nebentan (YM598 free base) is a potent, selective and orally active non-peptide endothelin ETA receptor antagonist through the modification of Bosentan (HY-A0013). Nebentan inhibits [ 125I] endothelin-1 binding to cloned human endothelin ETA and ETB receptor, with Ki of 0.697 nM and 569 nM, respectively. YM598 can ameliorate the progression of cor pulmonale and myocardial infarction in vivo.
  • HY-106994A
    Nebentan potassium

    YM598

    Endothelin Receptor Inflammation/Immunology Cardiovascular Disease
    Nebentan potassium (YM598) is a potent, selective and orally active non-peptide endothelin ETA receptor antagonist through the modification of Bosentan (HY-A0013). Nebentan potassium inhibits [ 125I] endothelin-1 binding to cloned human endothelin ETA and ETB receptor, with Ki of 0.697 nM and 569 nM, respectively. YM598 can ameliorate the progression of cor pulmonale and myocardial infarction in vivo.